In grade 2–3 astrocytoma, variations in FGFR4, KIT, NTRK2, and positive immunohistochemistry for ATRX and EGFR showed statistically significant results in univariate survival analysis (Figure S2). Here, ATRX is linked to astrocytoma (excluding glioblastoma).